Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations

Trial Profile

Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 May 2018

At a glance

  • Drugs Telavancin (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Apr 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
    • 27 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 30 Mar 2019.
    • 08 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top